{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:51:40Z","timestamp":1777517500962,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Guidance Project of Fujian Science and Technology Department","award":["2017Y0033"],"award-info":[{"award-number":["2017Y0033"]}]},{"name":"Weak Discipline Construction Project of Shanghai Municipal Health and Family Planning Commission","award":["2016ZB0301-01"],"award-info":[{"award-number":["2016ZB0301-01"]}]},{"name":"Young and Middle-aged Backbone Personnel Training Project of Fujian Province Health and Family Planning Commission","award":["2016-ZQN-38"],"award-info":[{"award-number":["2016-ZQN-38"]}]},{"name":"Science Foundation of Youths Project of Fujian Province Health and Family Planning Commission","award":["2016-1-56"],"award-info":[{"award-number":["2016-1-56"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00228-018-2600-8","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:56:56Z","timestamp":1542589016000},"page":"381-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Population pharmacokinetics of oxcarbazepine active metabolite in Chinese paediatric epilepsy patients and its application in individualised dosage regimens"],"prefix":"10.1007","volume":"75","author":[{"given":"Wei-wei","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-yong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-hua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-0876","authenticated-orcid":false,"given":"Chang-lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,19]]},"reference":[{"key":"2600_CR1","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1592\/phco.21.11.904.34513","volume":"21","author":"TA Glauser","year":"2001","unstructured":"Glauser TA (2001) Oxcarbazepine in the treatment of epilepsy. Pharmacotherpay 21:904\u2013919. \n                    https:\/\/doi.org\/10.1592\/phco.21.11.904.34513","journal-title":"Pharmacotherpay"},{"key":"2600_CR2","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1212\/01.wnl.0000186800.18456.72","volume":"65","author":"JE Pi\u00f1a-Garza","year":"2005","unstructured":"Pi\u00f1a-Garza JE, Espinoza R, Nordli D, Bennett DA, Spirito S, Stites TE, Tang D, Sturm Y (2005) Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 65:1370\u20131375. \n                    https:\/\/doi.org\/10.1212\/01.wnl.0000186800.18456.72","journal-title":"Neurology"},{"key":"2600_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","volume":"25","author":"SI Johannessen","year":"2003","unstructured":"Johannessen SI, Battino D, Berry DJ, Bialer M, Kr\u00e4mer G, Tomson T, Patsalos PN (2003) Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25:347\u2013363. \n                    https:\/\/doi.org\/10.1097\/00007691-200306000-00016","journal-title":"Ther Drug Monit"},{"key":"2600_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.seizure.2015.07.018","volume":"31","author":"A Sattler","year":"2015","unstructured":"Sattler A, Schaefer M, May TW (2015) Relationship between mono-hydroxy-carbazepine serum concentrations and adverse effects in patients on oxcarbazepine monotherapy. Seizure 31:149\u2013154. \n                    https:\/\/doi.org\/10.1016\/j.seizure.2015.07.018","journal-title":"Seizure"},{"key":"2600_CR5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.eplepsyres.2006.01.011","volume":"69","author":"S Striano","year":"2006","unstructured":"Striano S, Striano P, Di Nocera P, Italiano D, Fasiello C, Ruosi P, Bilo L, Pisani F (2006) Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy. Epilepsy Res 69:170\u2013176. \n                    https:\/\/doi.org\/10.1016\/j.eplepsyres.2006.01.011","journal-title":"Epilepsy Res"},{"key":"2600_CR6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E (2008) Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239\u20131276. \n                    https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x","journal-title":"Epilepsia"},{"key":"2600_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2165\/00023210-200115020-00005","volume":"15","author":"K Wellington","year":"2001","unstructured":"Wellington K, Goa KL (2001) Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 15:137\u2013163. \n                    https:\/\/doi.org\/10.2165\/00023210-200115020-00005","journal-title":"CNS Drugs"},{"key":"2600_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","volume":"42","author":"TW May","year":"2003","unstructured":"May TW, Korn-Merker E, Rambeck B (2003) Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 42:1023\u20131042. \n                    https:\/\/doi.org\/10.2165\/00003088-200342120-00002","journal-title":"Clin Pharmacokinet"},{"key":"2600_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","volume":"24","author":"G Flesch","year":"2004","unstructured":"Flesch G (2004) Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24:185\u2013203. \n                    https:\/\/doi.org\/10.2165\/00044011-200424040-00001","journal-title":"Clin Drug Investig"},{"key":"2600_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/sj.tpj.6500171","volume":"3","author":"C Guillemette","year":"2003","unstructured":"Guillemette C (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3:136\u2013158. \n                    https:\/\/doi.org\/10.1038\/sj.tpj.6500171","journal-title":"Pharmacogenomics J"},{"key":"2600_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2217\/pgs.14.186","volume":"16","author":"CL Ma","year":"2015","unstructured":"Ma CL, Wu XY, Jiao Z, Hong Z, Wu ZY, Zhong MK (2015) SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy. Pharmacogenomics 16:347\u2013360. \n                    https:\/\/doi.org\/10.2217\/pgs.14.186","journal-title":"Pharmacogenomics"},{"key":"2600_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00228-016-2157-3","volume":"73","author":"Y Lu","year":"2016","unstructured":"Lu Y, Fang Y, Wu X, Ma C, Wang Y, Xu L (2016) Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy. Eur J Clin Pharmacol 73:1\u20139. \n                    https:\/\/doi.org\/10.1007\/s00228-016-2157-3","journal-title":"Eur J Clin Pharmacol"},{"key":"2600_CR13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2174\/1381612043384844","volume":"10","author":"DJ Begley","year":"2004","unstructured":"Begley DJ (2004) ABC transporters and the blood-brain barrier. Curr Pharm Des 10:1259\u20131312. \n                    https:\/\/doi.org\/10.2174\/1381612043384844","journal-title":"Curr Pharm Des"},{"key":"2600_CR14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1046\/j.1528-1157.2003.42802.x","volume":"44","author":"SM Sisodiya","year":"2003","unstructured":"Sisodiya SM, Thom M (2003) Widespread upregulation of drug-resistance proteins in fatal human status epilepticus. Epilepsia 44:261\u2013264. \n                    https:\/\/doi.org\/10.1046\/j.1528-1157.2003.42802.x","journal-title":"Epilepsia"},{"key":"2600_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrn1728","volume":"6","author":"W L\u00f6scher","year":"2005","unstructured":"L\u00f6scher W, Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591\u2013602. \n                    https:\/\/doi.org\/10.1038\/nrn1728","journal-title":"Nat Rev Neurosci"},{"key":"2600_CR16","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1097\/00001756-200111160-00037","volume":"12","author":"H Potschka","year":"2001","unstructured":"Potschka H, Fedrowitz M, L\u00f6scher W (2001) P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12:3557\u20133560. \n                    https:\/\/doi.org\/10.1097\/00001756-200111160-00037","journal-title":"Neuroreport"},{"key":"2600_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1124\/jpet.301.1.7","volume":"301","author":"W L\u00f6scher","year":"2002","unstructured":"L\u00f6scher W, Potschka H (2002) Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 301:7\u201314. \n                    https:\/\/doi.org\/10.1124\/jpet.301.1.7","journal-title":"J Pharmacol Exp Ther"},{"key":"2600_CR18","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/j.1528-1167.2005.00265.x","volume":"46","author":"N Marchi","year":"2005","unstructured":"Marchi N, Guiso G, Rizzi M, Pirker S, Novak K, Czech T, Baumgartner C, Janigro D, Caccia S, Vezzani A (2005) A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia 46:1613\u20131619. \n                    https:\/\/doi.org\/10.1111\/j.1528-1167.2005.00265.x","journal-title":"Epilepsia"},{"key":"2600_CR19","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","volume":"52","author":"C Zhang","year":"2011","unstructured":"Zhang C, Zuo Z, Kwan P, Baum L (2011) In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia 52:1894\u20131904. \n                    https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03140.x","journal-title":"Epilepsia"},{"key":"2600_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.yebeh.2011.02.015","volume":"21","author":"H Meng","year":"2011","unstructured":"Meng H, Guo G, Ren J, Zhou H, Ge Y, Guo Y (2011) Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav 21:27\u201330. \n                    https:\/\/doi.org\/10.1016\/j.yebeh.2011.02.015","journal-title":"Epilepsy Behav"},{"key":"2600_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/FPC.0b013e328338073a","volume":"20","author":"WJ Kim","year":"2010","unstructured":"Kim WJ, Lee JH, Yi J, Cho YJ, Heo K, Lee SH, Kim SW, Kim MK, Kim KH, In Lee B, Lee MG (2010) A nonsynonymous variation in MRP2\/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics 20:249\u2013256. \n                    https:\/\/doi.org\/10.1097\/FPC.0b013e328338073a","journal-title":"Pharmacogenet Genomics"},{"key":"2600_CR22","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","volume":"64","author":"C Zhang","year":"2012","unstructured":"Zhang C, Kwan P, Zhong Z, Baum L (2012) The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 64:930\u2013942. \n                    https:\/\/doi.org\/10.1016\/j.addr.2011.12.003","journal-title":"Adv Drug Deliv Rev"},{"key":"2600_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/pgs.12.180","volume":"14","author":"YG Puranik","year":"2013","unstructured":"Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd J, Remmel RP, Leppik IE, Lamba JK (2013) Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 14:35\u201345. \n                    https:\/\/doi.org\/10.2217\/pgs.12.180","journal-title":"Pharmacogenomics"},{"key":"2600_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2165\/00003088-198611050-00004","volume":"11","author":"B Whiting","year":"1986","unstructured":"Whiting B, Kelman AW, Grevel J (1986) Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet 11:387\u2013401. \n                    https:\/\/doi.org\/10.2165\/00003088-198611050-00004","journal-title":"Clin Pharmacokinet"},{"key":"2600_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0009-9236(03)00124-3","volume":"74","author":"WM Sallas","year":"2003","unstructured":"Sallas WM, Milosavljev S, D\u2019Souza J, Hossain M (2003) Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther 74:138\u2013149. \n                    https:\/\/doi.org\/10.1016\/S0009-9236(03)00124-3","journal-title":"Clin Pharmacol Ther"},{"key":"2600_CR26","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/aps.2014.76","volume":"35","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhang HN, Niu CH, Gao P, Chen YJ, Peng J, Liu MC, Xu H (2014) Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol Sin 35:1342\u20131350. \n                    https:\/\/doi.org\/10.1038\/aps.2014.76","journal-title":"Acta Pharmacol Sin"},{"key":"2600_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.dmpk.2014.12.002","volume":"30","author":"I Sugiyama","year":"2015","unstructured":"Sugiyama I, Bouillon T, Yamaguchi M, Suzuki H, Hirota T, Fink M (2015) Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities. Drug Metab Pharmacokinet 30:160\u2013167. \n                    https:\/\/doi.org\/10.1016\/j.dmpk.2014.12.002","journal-title":"Drug Metab Pharmacokinet"},{"key":"2600_CR28","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1111\/bcp.13392","volume":"83","author":"C Rodrigues","year":"2017","unstructured":"Rodrigues C, Chiron C, Rey E, Dulac O, Comets E, Pons G, Jullien V (2017) Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children. Br J Clin Pharmacol 83:2695\u20132708. \n                    https:\/\/doi.org\/10.1111\/bcp.13392","journal-title":"Br J Clin Pharmacol"},{"key":"2600_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dong J, Ruiz-Garcia A, Sweeney K, Cronenberger C (2013) Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol 2:1\u20138. \n                    https:\/\/doi.org\/10.1038\/psp.2013.26","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2600_CR30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"G Schwartz","year":"2009","unstructured":"Schwartz G, Mu\u00f1oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637. \n                    https:\/\/doi.org\/10.1681\/ASN.2008030287","journal-title":"J Am Soc Nephrol"},{"key":"2600_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0031-3955(16)36251-4","volume":"34","author":"GJ Schwartz","year":"1987","unstructured":"Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Am 34:571\u2013590. \n                    https:\/\/doi.org\/10.1016\/S0031-3955(16)36251-4","journal-title":"Pediatr Clin N Am"},{"key":"2600_CR32","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo YA, Anderson B (2013) A pharmacokinetic standard for babies and adults. J Pharm Sci 102:2941\u20132952. \n                    https:\/\/doi.org\/10.1002\/jps.23574","journal-title":"J Pharm Sci"},{"key":"2600_CR33","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s11095-012-0668-x","volume":"29","author":"C Wang","year":"2012","unstructured":"Wang C, Peeters MY, Allegaert K, Oudalblas HV, Krekels EH, Tibboel D, Danhof M, Knibbe CA (2012) A bodyweight-dependent allometric exponent for scaling clearance across the human life-span. Pharm Res 29:1570\u20131581. \n                    https:\/\/doi.org\/10.1007\/s11095-012-0668-x","journal-title":"Pharm Res"},{"key":"2600_CR34","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF01061469","volume":"20","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511\u2013528. \n                    https:\/\/doi.org\/10.1007\/BF01061469","journal-title":"J Pharmacokinet Biopharm"},{"key":"2600_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10928-008-9099-z","volume":"35","author":"K Tunblad","year":"2008","unstructured":"Tunblad K, Lindbom L, Mcfadyen L, Jonsson EN, Marshall S, Karlsson MO (2008) The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J Pharmacokinet Pharmacodyn 35:503\u2013526. \n                    https:\/\/doi.org\/10.1007\/s10928-008-9099-z","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2600_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00228-005-0927-4","volume":"61","author":"CE Staatz","year":"2005","unstructured":"Staatz CE, Duffull SB, Kiberd B, Fraser AD, Tett SE (2005) Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol 61:507\u2013516. \n                    https:\/\/doi.org\/10.1007\/s00228-005-0927-4","journal-title":"Eur J Clin Pharmacol"},{"key":"2600_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/FTD.0b013e318284ef11","volume":"35","author":"V Gotta","year":"2013","unstructured":"Gotta V, Buclin T, Csajka C, Widmer N (2013) Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes. Ther Drug Monit 35:150\u2013167. \n                    https:\/\/doi.org\/10.1097\/FTD.0b013e318284ef11","journal-title":"Ther Drug Monit"},{"key":"2600_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","volume":"33","author":"VDM Af","year":"2011","unstructured":"Af VDM, Marcus MA, Touw DJ, Proost JH, Neef C (2011) Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit 33:133\u2013146. \n                    https:\/\/doi.org\/10.1097\/FTD.0b013e31820f40f8","journal-title":"Ther Drug Monit"},{"key":"2600_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1365-2710.2010.01215.x","volume":"36","author":"IB Bondareva","year":"2011","unstructured":"Bondareva IB, Hall RW, Andreeva OV, Student KIB (2011) Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy. J Clin Pharm Ther 36:625\u2013636. \n                    https:\/\/doi.org\/10.1111\/j.1365-2710.2010.01215.x","journal-title":"J Clin Pharm Ther"},{"key":"2600_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/FTD.0b013e31826aabc3","volume":"34","author":"NH Holford","year":"2012","unstructured":"Holford NH, Buclin T (2012) Safe and effective variability-a criterion for dose individualization. Ther Drug Monit 34:565\u2013568. \n                    https:\/\/doi.org\/10.1097\/FTD.0b013e31826aabc3","journal-title":"Ther Drug Monit"},{"key":"2600_CR41","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/bja\/aen248","volume":"101","author":"A KJS","year":"2008","unstructured":"KJS A, Anderson BJ, NHG H, Hall RW, Young T, Shephard B, Desai NS, Barton BA, NEOPAIN Trial Investigators Group (2008) Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 101:680\u2013689. \n                    https:\/\/doi.org\/10.1093\/bja\/aen248","journal-title":"Br J Anaesth"},{"key":"2600_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2125.2006.02725.x","volume":"63","author":"BJ Anderson","year":"2007","unstructured":"Anderson BJ, Allegaert K, Jn VDA, Cossey V, Holford NH (2007) Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 63:75\u201384. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02725.x","journal-title":"Br J Clin Pharmacol"},{"key":"2600_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2125.2006.02622.x","volume":"61","author":"I Mahmood","year":"2006","unstructured":"Mahmood I (2006) Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 61:545\u2013557. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02622.x","journal-title":"Br J Clin Pharmacol"},{"key":"2600_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2165\/11319350-000000000-00000","volume":"49","author":"MY Peeters","year":"2010","unstructured":"Peeters MY, Allegaert K, Oudalblas HBV, Cella M, Tibboel D, Danhof M, Knibbe CAJ (2010) Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet 49:269\u2013275. \n                    https:\/\/doi.org\/10.2165\/11319350-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"2600_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200645010-00001","volume":"45","author":"S Bj\u00f6rkman","year":"2006","unstructured":"Bj\u00f6rkman S (2006) Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet 45:1\u201311. \n                    https:\/\/doi.org\/10.2165\/00003088-200645010-00001","journal-title":"Clin Pharmacokinet"},{"key":"2600_CR46","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","volume":"51","author":"IH Bartelink","year":"2012","unstructured":"Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB, Shaw PJ, Nath CE, Hempel G, Zwaveling J, Danhof M, Knibbe CA (2012) Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet 51:331\u2013345. \n                    https:\/\/doi.org\/10.2165\/11598180-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"2600_CR47","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/emj.2009.087288","volume":"28","author":"MD Luscombe","year":"2011","unstructured":"Luscombe MD, Owens BD, Burke D (2011) Weight estimation in paediatrics: a comparison of the APLS formula and the formula \u201cweight=3(age)+7\u201d. Emerg Med J 28:590\u2013593. \n                    https:\/\/doi.org\/10.1136\/emj.2009.087288","journal-title":"Emerg Med J"},{"key":"2600_CR48","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.resuscitation.2014.03.313","volume":"85","author":"C Flannigan","year":"2014","unstructured":"Flannigan C, Bourke TW, Sproule A, Stevenson M, Terris M (2014) Are APLS formulae for estimating weight appropriate for use in children admitted to PICU? Resuscitation 85:927\u2013931. \n                    https:\/\/doi.org\/10.1016\/j.resuscitation.2014.03.313","journal-title":"Resuscitation"},{"key":"2600_CR49","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","volume":"54","author":"J Ding","year":"2015","unstructured":"Ding J, Wang Y, Lin W, Wang C, Zhao L, Li X, Zhao Z, Miao L, Jiao Z (2015) A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet 54:305\u2013317. \n                    https:\/\/doi.org\/10.1007\/s40262-014-0212-8","journal-title":"Clin Pharmacokinet"},{"key":"2600_CR50","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1124\/dmd.110.037192","volume":"39","author":"SJ Miyagi","year":"2011","unstructured":"Miyagi SJ, Collier AC (2011) The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver. Drug Metab Dispos 39:912\u2013919. \n                    https:\/\/doi.org\/10.1124\/dmd.110.037192","journal-title":"Drug Metab Dispos"},{"key":"2600_CR51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fphar.2016.00437","volume":"7","author":"E Barletta","year":"2016","unstructured":"Barletta E, Mehboob H, Ram\u00edrez J, Mirkov S, Zhang M, Liu W (2016) Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol 7:437. \n                    https:\/\/doi.org\/10.3389\/fphar.2016.00437","journal-title":"Front Pharmacol"},{"key":"2600_CR52","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1111\/j.1528-1167.2010.02771.x","volume":"51","author":"I Wegner","year":"2010","unstructured":"Wegner I, Edelbroek P, de Haan GJ, Lindhout D, Sander JW (2010) Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. Epilepsia 51:2500\u20132502. \n                    https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02771.x","journal-title":"Epilepsia"},{"key":"2600_CR53","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","volume":"21","author":"TW May","year":"1999","unstructured":"May TW, Rambeck B, J\u00fcrgens U (1999) Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 21:175\u2013181. \n                    https:\/\/doi.org\/10.1097\/00007691-199904000-00007","journal-title":"Ther Drug Monit"},{"key":"2600_CR54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2125.1993.tb00378.x","volume":"36","author":"A Tartara","year":"1993","unstructured":"Tartara A, Galimberti CA, Manni R, Morini R, Limido G, Gatti G, Bartoli A, Strada G, Perucca E (1993) The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 36:366\u2013368. \n                    https:\/\/doi.org\/10.1111\/j.1365-2125.1993.tb00378.x","journal-title":"Br J Clin Pharmacol"},{"key":"2600_CR55","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1212\/WNL.57.5.864","volume":"57","author":"R Sachdeo","year":"2001","unstructured":"Sachdeo R, Beydoun A, Schachter S, Vazquez B, Schaul N, Mesenbrink P, Kramer L, D'Souza J (2001) Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 57:864\u2013871. \n                    https:\/\/doi.org\/10.1212\/WNL.57.5.864","journal-title":"Neurology"},{"key":"2600_CR56","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","volume":"41","author":"G Barcs","year":"2000","unstructured":"Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, Moore A, Flesch G, Kramer L, D'Souza J (2000) Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 41:1597\u20131607. \n                    https:\/\/doi.org\/10.1111\/j.1499-1654.2000.001597.x","journal-title":"Epilepsia"},{"key":"2600_CR57","first-page":"A524","volume":"52","author":"JR Nedelman","year":"1999","unstructured":"Nedelman JR, Hossain M, Chang SW (1999) Oxcarbazepine: analysis of concentration-efficacy\/safety relationships. Neurology 52:A524","journal-title":"Neurology"},{"key":"2600_CR58","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1528-1157.1993.tb02397.x","volume":"34","author":"H Kubov\u00e1","year":"1993","unstructured":"Kubov\u00e1 H, Mares P (1993) Anticonvulsant action of oxcarbazepine,hydroxycarbazepine, and carbazepine against metrazol-induced motor seizures in developing rats. Epilepsia 34:188\u2013192","journal-title":"Epilepsia"},{"key":"2600_CR59","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/j.ejps.2017.05.034","volume":"109S","author":"NJ Antunes","year":"2017","unstructured":"Antunes NJ, van Dijkman SC, Lanchote VL, Wichert-Ana L, Coelho EB, Alexandre JV, Takayanagui OM, Tozatto E, van Hasselt JGC, Della Pasqua O (2017) Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. Eur J Pharm Sci 109S:S116\u2013S123. \n                    https:\/\/doi.org\/10.1016\/j.ejps.2017.05.034","journal-title":"Eur J Pharm Sci"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2600-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2600-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2600-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T19:33:32Z","timestamp":1574105612000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2600-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,19]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2600-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,19]]},"assertion":[{"value":"7 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}